



Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 12<sup>th</sup> June 2019  
Ein Cyf / Our Ref: 19-E-021

☎ 01639 683312  
☎ 01639 648363

🖱 FOIA.Requests@wales.nhs.uk

Corporate Administration  
Headquarters  
1 Talbot Gateway  
Baglan  
Port Talbot, SA12 7BR

[Redacted]

[Redacted]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 17<sup>th</sup> May 2019. Your request sought information relating to Multiple Sclerosis (MS).

**1. In your Health Board how many patients have a diagnosis of Multiple Sclerosis (MS), regardless of whether they are currently on treatment?**

This information is not held centrally within the Health Board. This data would be held by GP practices within Primary Care.

**2. Of these MS patients, how many have been diagnosed with relapsing (RMS) or primary progressive (PPMS) MS;**

As above – see Q1

**3. How many patients with Multiple Sclerosis have been treated with disease modifying drugs in the past 6 months. Please include all patients whose treatment is ongoing, even those with infrequent dosing schedules (e.g. Lemtrada, Mavenclad, Ocrevus). Please provide the total number of patients by treatment for the following disease modifying drugs:**

Drugs	Number of Patients
<b>Aubagio (teriflunomide)</b>	<5*
<b>Avonex (interferon beta-1a)</b>	9
<b>Betaferon (interferon beta-1b)</b>	0
<b>Brabio (glatiramer acetate)</b>	0
<b>Copaxone (glatiramer acetate)</b>	24
<b>Extavia (beta interferon-1b)</b>	0



<b>Gilenya (fingolimod)</b>	26
<b>Lemtrada (alemtuzumab)</b>	7
<b>Mavenclad (cladribine)</b>	<5*
<b>Ocrevus (Ocrelizumab)</b>	58
<b>Plegridy (Peginterferon beta-1a)</b>	23
<b>Rebif (beta interferon-1a)</b>	5
<b>Tecfidera (dimethyl fumarate)</b>	53
<b>Tysabri (natalizumab)</b>	46
<b>Zinbryta (daclizumab)</b>	0
<b>Ampyra (Fampyra)</b>	9

\*Where less than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2<sup>nd</sup> Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



Pam Wenger  
**Director of Corporate Governance**

